Plasma membrane-coated nanoparticles and membrane vesicles to orchestrate multimodal antitumor immunity.

ABSTRACT:

Background

A number of immunotherapeutic approaches have been developed and are entering the clinic. Bispecific antibodies (BsAbs) are one of these modalities and induce robust efficacy by endogenous T cells in several hematological malignancies. However, most of the treated patients experience only a temporary benefit. Currently available BsAbs provide only anti-CD3 antibody-mediated T-cell stimulation, but not the costimulation or cytokine signaling essential for full T-cell activation. Here, we hypothesized that the simultaneous input of more comprehensive signals would elicit more robust and durable effector T-cell functions.

Methods

We genetically engineered the leukemia cell line K562 to express BsAbs, costimulatory ligands, cytokines, and blocking antibodies against i

SUBMITTER: Ito Y 

PROVIDER: S-EPMC11784344 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature